Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FJZHT03 is a Traditional Chinese Medicine (TCM) formulation developed by the Changchun University of Chinese Medicine (formerly Changchun Traditional Chinese Medicine College) specifically for the treatment of stable angina pectoris. As a multi-component herbal preparation, it is designed to address the underlying pathology of coronary heart disease by invigorating blood circulation and resolving blood stasis. Pharmacological studies indicate that FJZHT03 exerts its therapeutic effects by inhibiting platelet aggregation, reducing blood viscosity, and improving myocardial blood supply. It is typically administered orally and has been evaluated in clinical trials in China for its ability to reduce the frequency of anginal attacks and improve electrocardiographic parameters in patients with stable coronary artery disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FJZHT03.